• Glaukos recently raised its 2026 net sales guidance to US$680 million–US$700 million and reported second-quarter 2026 sales of US$185.61 million, up from US$124.12 million a year earlier, while keeping net losses relatively stable.
• At the same time, Glaukos completed patient enrollment in its pivotal U.S. PRESERFLO MicroShunt study, highlighting tangible progress in expanding its glaucoma device pipeline toward a potential future FDA submission.
• Now we’ll explore how the upgraded 2026 net sales guidance reshapes Glaukos’ existing investment narrative and longer-term business outlook.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Glaukos Investment Narrative Recap

To own Glaukos, you need to believe its combination of glaucoma devices, corneal therapies, and ocular pharmaceuticals can translate rising procedure volumes into a path toward profitability, despite continued net losses. The raised 2026 net sales guidance to US$680 million–US$700 million reinforces revenue momentum, but it does not remove key near term risks around reimbursement pressure and execution on product launches, which still look like the most important swing factors for the story.

The completion of patient enrollment in the pivotal U.S. PRESERFLO MicroShunt study feels especially relevant here, because it underlines how much of Glaukos’ future hinges on executing late stage programs. PRESERFLO sits alongside iDose and Epioxa as central to the next wave of glaucoma and corneal growth catalysts, but also adds to the company’s exposure to trial outcomes, regulatory decisions, and eventual reimbursement decisions that could influence whether today’s higher sales guidance proves sustainable.

Yet, investors should also be aware that if reimbursement tightens faster than expected or late stage trials like PRESERFLO disappoint…

Glaukos' narrative projects $1.1 billion revenue and $113.0 million earnings by 2029. This requires 25.5% yearly revenue growth and a $302.3 million earnings increase from -$189.3 million today.

Uncover how Glaukos' forecasts yield a $165.00 fair value, a 3% downside to its current price.

Exploring Other Perspectives

Before this update, the most optimistic analysts were assuming revenue could reach about US$1.3 billion by 2029, with earnings near US$178.8 million. Compared with the baseline view that flags broad reimbursement and execution risks, these bulls focus on the upside from products like PRESERFLO, which the latest trial progress directly touches, showing how differently reasonable people can frame Glaukos’ future and why fresh data like this may shift those narratives over time.

Explore 4 other fair value estimates on Glaukos - why the stock might be worth 20% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Glaukos research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Glaukos research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Glaukos' overall financial health at a glance.

No Opportunity In Glaukos?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Find 53 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.